RG 7716Alternative Names: RG-7716
Latest Information Update: 12 Nov 2016
At a glance
- Originator Roche
- Class Eye disorder therapies
- Mechanism of Action Angiopoietin-2 modulators; Vascular endothelial growth factor A modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Age-related macular degeneration; Choroidal neovascularisation
Most Recent Events
- 01 Jun 2015 Phase-II clinical trials in Choroidal neovascularisation in USA (Intravitreous)